Uta Kemmerich-Keil

Born on Dezember 27, 1966, in Attendorn, Germany
Uta Kemmerich-Keil, Member of the Supervisory Board
  • Nationality: German
  • Member of the Supervisory Boards of various commercial
  • Former CEO of Procter & Gamble Personal Healthcare International, Geneva, Switzerland
  • Member of the Supervisory Board of LANXESS AG since 2026 (appointed until 2030)

 

Ms. Kemmerich-Keil completed a Master of Economics at the University of Freiburg, Germany. She also studied French literature in parallel, obtaining a Master of Arts. She was awarded a Licence Franco-Allemande (Bachelor of Arts) at the Nouvelle Sorbonne Paris III in France.

After two years as a research associate at the Institute of Romance Philology at the University of Freiburg, Ms. Kemmerich-Keil began her career in 1996 as Senior Financial Auditor in the Internal Audit department of Hoechst AG in Frankfurt am Main. In 1999, she moved to Merck KGaA in Darmstadt, where she held various positions until 2018. From 2001, she was Head of Financial Controlling there in the global Pharmaceuticals business sector. In 2005, she became Head of Corporate M&A and Merger Integration. From 2007 to 2012, she was additionally Head of
Corporate Finance with Treasury and Investor Relations. In 2013, she switched to business operations, as CEO of Allergopharma GmbH & Co. KG and Head of the global Allergy Business Unit.
From 2014 to 2018, Ms. Kemmerich-Keil was then responsible as CEO for the Merck Consumer Health division. In 2018, she moved to Switzerland and was CEO and Head of Personal Healthcare International at Procter & Gamble until the end of 2020, before becoming a full-time supervisory board member at various companies from 2021. 

Ms. Kemmerich-Keil therefore has extensive decades of experience in various operational management functions at major international corporations in the healthcare and consumer goods industry, focusing on restructuring and digitalization. She also has excellent knowledge in the field of finance, in particular in controlling, merger & acquisitions, treasury, and investor relations.

Memberships in the following other statutory supervisory boards:
  • LANXESS Deutschland GmbH
  • Beiersdorf AG, Hamburg (publicly listed)
  • Schott AG, Mainz
Memberships in the following comparable domestic and foreign controlling bodies:
  • British American Tobacco plc., London, United Kingdom (publicly listed)
  • Klosterfrau Healthcare Group, Zurich, Switzerland
  • Mitglied im Beirat der Röchling SE & Co. KG, Mannheim 

Cologne, May 2026